Trial results on pirepemat for falls in Parkinson’s disease due soon

25 January 2025

A red pen checks the words "Clinical" and "Trials" on a clipboard.

All patients have completed final follow-up visits in a Phase 2 clinical trial testing pirepemat, an oral treatment designed to reduce falls in Parkinson’s disease, and top-line results are expected in the first quarter, said developer Irlab Therapeutics.

The development “marks an important milestone in our clinical development program for pirepemat,” Kristina Torfgård, PhD, CEO of Irlab, said in a company press release. “We are delighted that as many as 87% of the enrolled patients completed the study indicating a low drop-out rate and that the participants enrolled in the current study are reported to be very satisfied during the treatment period.”

Falls are a common problem that can lead to disabling outcomes in people with Parkinson’s disease. Pirepemat, previously known as IRL752, is designed to reduce the risk of falls by improving the strength of certain nerve signals in the brain. The therapy acts to modulate the activity of nerve cell receptors 5HT7 and alpha-2, resulting in increased levels of dopamine and noradrenaline, two neurotransmitters, or chemical messengers.

Recommended Reading

An elderly woman is shown moving about using a walker.

Wearable sensors may help to quickly spot patients at risk of falls

Available data indicate fewer falls

The Phase 2b REACT-PD trial (NCT05258071) tested two doses of pirepemat against a placebo in adults with Parkinson’s disease. In the study, which finished enrollment last year, participants were given the medication for three months. The main goal was to compare the rate of falls during treatment to the rate of falls in the month before entering the study.

Irlab said available data from the study suggest that falls were less frequent during the study period than in the month before. Since the data are still blinded, it’s not yet clear whether that was due to a reduction in risk among patients given pirepemat, the company said. Still, “it can be concluded that participation in this study leads to a reduction in fallrates,” said Joakim Tedroff, MD, PhD, the company’s chief medical officer.

The post Trial results on pirepemat for falls in Parkinson’s disease due soon appeared first on Parkinson's News Today.

https://parkinsonsnewstoday.com/news/trial-results-pirepemat-falls-parkinsons-disease-due-soon/

Parkinsons News Today

Categories

0 Comments

Submit a Comment

Parkinsons, Odd behaviour and Medications

Parkinsons, Odd behaviour and Medications

Do you have a friend or loved one with Parkinsons ? You reckon that would be bad enough ? Is their behaviour a bit (or a lot or even dangerously) out of character? It may be the drugs they are taking and not their real self or the disease!Please read ALL of this post...

Introduction and Excuse me!

Introduction and Excuse me!

Pardon me, while I get this social media enterprise working. It has taken me 12 months to get this far with this editorial labyrinth. My former pre Parkinson’s self would have had this whipped up in a week or two, reality changes ability, however I won’t let it kill...

They Call me Shuffles

They Call me Shuffles

    A diagnosis with Parkinson's changes a lot of things: Motor function, non-motor functions, but maybe even more powerful is the changes in social interactions. I personally don't mind being called "Shuffles" now, I did at first (8 or so years ago I think), I...